checkAd
    Startseite > Aktien > Immutep > Nachrichten
    Immutep Aktie
    3,0000
     
    USD
    +6,38 %
    +0,1800 USD
    Letzter Kurs 02:00:00 Nasdaq
    2,9900
     
    USD
    400 STK
    Geldkurs 06.05.24
    3,0000
     
    USD
    3.900 STK
    Briefkurs 06.05.24
    ISIN: US45257L1089 · WKN: A2H8YL · SYM: IMMP · Australien

    Neueste Nachrichten

    Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
    02.05.24 · globenewswire · Immutep
    Immutep Quarterly Activities Report Q3 FY24
    29.04.24 · globenewswire · Immutep
    Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
    24.04.24 · globenewswire · Immutep
    Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
    18.04.24 · globenewswire · Immutep
    Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
    17.04.24 · globenewswire · Immutep
    Immutep Announces First Clinical Data from 90mg Dosing of Efti
    05.03.24 · globenewswire · Immutep
    Immutep Quarterly Activities Report Q2 FY24
    30.01.24 · globenewswire · Immutep
    First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer
    04.01.24 · globenewswire · Immutep
    Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
    21.12.23 · globenewswire · Immutep
    Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
    22.11.23 · globenewswire · Immutep
    Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
    09.11.23 · globenewswire · Immutep
    Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
    06.11.23 · globenewswire · Immutep